Preclinical and clinical insights of sodium glucose cotransporter 2 inhibitors in management of diabetes and it s complications

Abstract

Diabetes is a metabolic illness that is characterized by raised blood glucose levels. This elevated blood glucose level leads to associated consequences such as cardiovascular cerebrovascular nephropathy neuropathy retinopathy cataract and foot damage. persons who have diabetes have a risk of cardiovascular disease that is two to three times higher than the risk that persons who do not have diabetes have. Oral anti diabetic medicines that are more recent in development are sodium glucose co transporter inhibitors. In spite of the fact that the evolution of contemporary medicine has led to the introduction of current pharmacotherapeutics such as biguanides sulfonylureas and thiazolidinediones amongst others there is still a want for the development of new medications. Since there is no medication that has been proved to alter the progression of diabetic problems the only option is to strictly regulate glycemic levels using insulin. As a result of the fact that numerous studies have demonstrated that SGLT2 has a significantly lower risk of mortality from cardiovascular causes it may be possible to unlock other issues associated with diabetes. A comparison of the SGLT2 inhibitors is going to be the focus of this particular investigation. As a result the purpose of this research is to evaluate the efficacy of SGLT2 inhibitors including Canagliflozin Dapagliflozin Empagliflozin and Remogliflozin in both animal models and in human patients who have diabetes and the complications that are sometimes associated with it.